Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Quipt Home Medical Corp T.QIPT

Alternate Symbol(s):  QIPT

Quipt Home Medical Corp. is a home medical equipment provider. The Company specializes in improving the home management of chronic illness through the application of telehealth systems and automated distribution. It provides in-home monitoring and disease management services, including end-to-end respiratory solutions for patients in the United States. It offers nebulizers, oxygen concentrators, continuous positive airway pressure (CPAP) and Bilevel Positive Airway Pressure (BiPAP) units; traditional and non-traditional medical respiratory equipment and services, and non-invasive ventilation equipment, supplies, and services. The Company's product offerings include the management of several chronic disease states focusing on patients with heart or pulmonary disease, sleep disorders, reduced mobility, and other chronic health conditions. Its products and services consist of sleep apnea and pap treatment, home ventilation, daily and ambulatory aides, and respiratory equipment rental.


TSX:QIPT - Post by User

Bullboard Posts
Post by Trademark11on Aug 29, 2018 4:59am
267 Views
Post# 28533780

Q4 guided to 7.1%+ q/q growth

Q4 guided to 7.1%+ q/q growthMr. Crawford confirmed previous guidance that PHM should meet or exceed 78 million for the annual revenue.  In the first three quarters they have generated $56.8 million USD, which leaves Q4 revenue at $21.4 million USD, representing Q/Q growth of 7.1%.  At a conservative view of 20% EBITDA for Q4, we are looking at $4.28 million, a Q/Q growth of 16.7%.  Mr. Mehta mentioned that they can absorb another 8-10% revenue growth without sustaining increased overhead, so the extra $1.7 million Q4/Q3 should fall right to the bottom line, giving the first quarter (and correct me if I'm wrong) in their history where they will have a positive net earnings.  This is in absense of the tuck in aquisitions, which they have guided to two deals in the next 4 months.  Taking those into consideration, and the details therein, may likely set the SP on a parabolic rise in the short to intermediate term.  
Bullboard Posts